Read More

Aptar Awarded U.S. FDA Contract To Study Opportunities For Low Global Warming Potential Propellants For Metered Dose Inhalers; The Contracted Work, Including “Optional Contract Line Items”, Is Valued At Up To ~ $6M

AptarGroup, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, is announcing a contract with the U.S. Food and Drug Administration (FDA) to study the challenges

ATR